

TRANSLATIONAL BIOMARKERS IN DRUG DEVELOPMENT: Bench to Bedside and Back Again

In vitro diagnostic assays, whether companion or complimentary are an essential part of drug development, optimal patient stratification and outcomes management.

The presenters will discuss the uses of translational biomarkers in drug development, including examples of the more conventional “Bench to Bedside” role of biomarkers, as well as examples of “Bedside to Bench.”

As today’s translational biomarkers are tomorrow’s companion diagnostics, attention will be paid to biomarkers in this transition state and to the options for companion diagnostic development and commercialisation.

Topics:

- ▶ Biomarker use in preclinical disease models
- ▶ Exploratory biomarkers for predictive safety
- ▶ New approaches to translation: *ex vivo*-derived biomarkers
- ▶ Alternatives approaches for companion diagnostic development

About the Presenters

Dr. Katherine T. Landschulz, Ph.D. – Associate Director, Covance Translational Biomarker Solutions

Katherine Landschulz received her Ph.D. in Human Genetics from Johns Hopkins University. She has 19 years of experience in drug development and biomarkers, serving in scientific roles from Drug Discovery through Translational Medicine at three major pharmaceutical companies. Dr. Landschulz joined Covance in 2010 as principal scientist, and assumed responsibility for the Translational Biomarker Solutions Laboratory in 2015.

Dr. Mark J Roberts Ph.D. - Senior Director, Diagnostics Development, Covance Drug Development

Mark Roberts received his PhD in Pharmaceutical Sciences from the University of Nottingham (UK) and has worked in the clinical diagnostics arena for over 20 years, holding senior positions in both the *in vitro* diagnostic and reference laboratory industries. He joined Covance in 2012 to lead the companion diagnostics initiative, designed to assist pharmaceutical and diagnostic companies in drug / companion diagnostic co-development.

Thursday, 23rd Feb 2017

BioM Biotech Cluster Development GmbH

Am Klopferspitz 19a, IZB-West

Germany-82152 Martinsried

Agenda

13:30 – 14:00 Welcome & registration

14:00 – 17:00 Workshop (including coffee break)

17:00 – 17:30 Networking & snack buffet

Audience

Drug developers working in the targeted / tailored therapeutics space. Of particular interest to drug developers less experienced in the field biomarkers and diagnostic development.

Please register free of charge: <http://events.bio-m.org/covance-registration>

Contact:

Martina- N. Muntean

T: +49 7121 958 4584

M: +49 152 2284 7143

E: Martina.Muntean@covance.com

[Learn more about our drug development solutions at www.covance.com](http://www.covance.com)

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

THE AMERICAS +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440

EUROPE/AFRICA +00.800.2682.2682 +44.1423.500888 | ASIA PACIFIC +800.6568.3000 +65.6.5686588

© Copyright 2016, Covance Inc.

